146 related articles for article (PubMed ID: 16303033)
1. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
Horn JR; Howden CW
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():20-4. PubMed ID: 16303033
[TBL] [Abstract][Full Text] [Related]
2. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
Howden CW
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
[TBL] [Abstract][Full Text] [Related]
3. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005.
Hunt RH
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():10-9. PubMed ID: 16303032
[TBL] [Abstract][Full Text] [Related]
4. Coprescribing proton pump inhibitors with other medications.
Garnett WR; Prescott J
Manag Care Interface; 2000 Sep; 13(9):71-6, 79. PubMed ID: 11142965
[TBL] [Abstract][Full Text] [Related]
5. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.
Saltiel E; Fask A
Clin Ther; 1999 Oct; 21(10):1812-9. PubMed ID: 10566575
[TBL] [Abstract][Full Text] [Related]
7. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
[TBL] [Abstract][Full Text] [Related]
8. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
Freston JW; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
[TBL] [Abstract][Full Text] [Related]
9. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
10. Review article: prevention of stress-related mucosal bleeding with proton-pump inhibitors.
Maton PN
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():45-52. PubMed ID: 16303037
[TBL] [Abstract][Full Text] [Related]
11. Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.
Katz PO
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():31-8. PubMed ID: 16303035
[TBL] [Abstract][Full Text] [Related]
12. Zegerid--immediate-release omeprazole.
Med Lett Drugs Ther; 2005 Apr; 47(1206):29. PubMed ID: 15821632
[TBL] [Abstract][Full Text] [Related]
13. A decade-long sour-taste sensation successfully treated with a proton-pump inhibitor.
Mantani N; Ito K; Kogure T; Hoshino A; Kawada E; Sakamoto H; Fujita K; Tamura J
J Oral Rehabil; 2005 Oct; 32(10):776-8. PubMed ID: 16159358
[TBL] [Abstract][Full Text] [Related]
14. Review article: the role of antisecretory therapy in the management of non-variceal upper gastrointestinal bleeding.
Triadafilopoulos G
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():53-8. PubMed ID: 16303038
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole-associated microscopic colitis: a case series.
Thomson RD; Lestina LS; Bensen SP; Toor A; Maheshwari Y; Ratcliffe NR
Am J Gastroenterol; 2002 Nov; 97(11):2908-13. PubMed ID: 12425567
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries.
Naseri E; Yenisehirli A
Eur J Pharmacol; 2006 Feb; 531(1-3):226-31. PubMed ID: 16438963
[TBL] [Abstract][Full Text] [Related]
18. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.
Pais SA; Nathwani RA; Dhar V; Nowain A; Laine L
Aliment Pharmacol Ther; 2006 Jun; 23(11):1607-13. PubMed ID: 16696810
[TBL] [Abstract][Full Text] [Related]
19. [A new blocker of proton pump pariet: pharmacological properties and effectiveness of clinical application].
Sheptulin AA
Klin Med (Mosk); 2001; 79(3):62-6. PubMed ID: 11490423
[No Abstract] [Full Text] [Related]
20. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis.
Kuroda M; Yoshida N; Ichikawa H; Takagi T; Okuda T; Naito Y; Okanoue T; Yoshikawa T
Int J Mol Med; 2006 Jan; 17(1):89-93. PubMed ID: 16328016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
